News Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
4.06 ^USD	-1.46%		-9.98%	-3.79%

Apr. 03	Top Midday Gainers	MT
Apr. 03	Vanda Pharmaceuticals Shares Soar After FDA Approval for Bipolar I Disorder Therapy	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Midday Gainers	Apr. 03	MT
Vanda Pharmaceuticals Shares Soar After FDA Approval for Bipolar I Disorder Therapy	Apr. 03	MT
VANDA Pharmaceuticals States A Fifth Amendment Claim Against The Government For Taking A Trade Secret	Apr. 03	AQ
Powell Speech Eyed, Intel Weighs on Sentiment as US Equity Futures Waver Premarket	Apr. 03	MT
Sector Update: Health Care Stocks Flat Pre-Bell Wednesday	Apr. 03	MT
Sector Update: Health Care	Apr. 03	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Bets Lean Towards Smaller Rate Cuts	Apr. 03	MT
Top Premarket Gainers	Apr. 03	MT
North American Morning Briefing : Powell Awaited as Inflation Fears Continue to Damp Mood	Apr. 03	DJ
Vanda Pharmaceuticals Secures FDA Approval for Bipolar I Disorder Therapy; Shares Rise Pre-Bell	Apr. 03	MT
US FDA approves Vanda's drug for treatment of bipolar disorder	Apr. 02	RE
US FDA approves Vanda's drug for bipolar disorder	Apr. 02	RE
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder	Apr. 02	PR
Vanda Pharmaceuticals' Fanapt (Iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder	Apr. 02	CI
Stocks to Watch : Intel, Vanda Pharmaceuticals, OneMedNet	Apr. 02	DJ
Vanda Pharmaceuticals Shares Jump 17% After FDA Approved Fanapt for Bipolar I Disorder	Apr. 02	DJ
Vanda Pharmaceuticals' Fanapt Gets FDA Approval for Bipolar I Disorder	Apr. 02	DJ
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA	Mar. 27	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA	Mar. 19	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA	Mar. 11	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Summary

Filters